



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/583,785
Filing Date	06/19/2006
First Named Inventor	Seeger
Art Unit	4411 1656
Examiner Name	Abu Chih-Min Kam
Attorney Docket Number	607927-01

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/CMK./		IDELL S., "Endothelium and disordered fibrin turnover in the injured lung: Newly recognized pathways." Crit. Care Med. (2002) vol. 30, pages 274-280	
		BERTOZZI, P. et al., "Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome." N. Engl. J. Med., (1990) vol. 30, pages 890-897	
		CAMPELL, E.J. et al., "Extracellular matrix injury during lung inflammation." Chest, (1987) vol. 92, pages 161-167	
		BURKHARDT, A., "Alveolitis and collapse in the pathogenesis of pulmonary fibrosis." Am. Rev. Respir. Dis. (1989) vol. 140, pages 513-524	
		CREUWELS, L.A.J.M. et al., "The pulmonary surfactant system: Biochemical and clinical aspects." Lung (1997) vol. 175, pages 1-39	
		HAGGSMANN, H.P. et al., "Surfactant-associated proteins: functions and structural variation." Comp. Biochem. Physiol. A: Mol. Integr. Physiol. (2001) vol. 129, pages 91-108.	
		CROUCH, E. et al., "Surfactant proteins A and D and pulmonary host defence." Annu. Rev. Physiol. (2001), vol. 63, pages 521-54.	
		WEAVER, T.E. et al., "Functions of surfactant proteins B and C." Annu. Rev. Physiol. (2001) vol. 63, pages 555-78	
		SISSON, T.H. et al., "Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes." Human Gene Therapy (1999), vol. 10, pages 2315-2323.	
/CMK./		LEVIN, E.G. et al., "Human hepatoma cell line plasminogen activator." J. Lab. Clin. Med. (1983), vol. 102, pages 500-508.	

Examiner Signature	/Chih Min Kam/	Date Considered	08/13/2010
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/583,785
		Filing Date	06/19/2006
		First Named Inventor	Seeger
		Art Unit	4444 1656
		Examiner Name	Abd Chih-Min Kam
Sheet 3	of 3	Attorney Docket Number	607927-01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/CMK./		PETER, K. et al., "Construction and in vitro testing of a novel Fab-Hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor Xa-dependent manner." Cardiovasc. Pharmacol., (2003), vol. 42, pages 237-244	
		KERR, D.E. et al., "Comparison of recombinant and synthetically formed monoclonal antibody-bet-lactamase conjugates for anticancer...." Bioconjugate Chem. (1999), vol. 10, pages 1084-1089.	
		LINDBLADH C. et al., "Use of genetically prepared enzyme conjugates in enzyme immunoassay." Trends Biochem Sci. (1993), vol. 18(8), pages 279-83.	
		SCHERMULY, R.T. et al., "Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (Va/Q) mismatch in a model of acute lung injury." Am. J. Respir. Crit. Care Med. (2000), vol. 161, pages 152-159.	
		CASTELLINO F.J. et al., "Structure and function of the plasminogen/plasmin system." Thromb Haemost (2005), vol. 93, pages 647-54.	
		DOBROVOLSKY A.B. et al., "The fibrinolysis system: Regulation of activity and physiologic functions of its main components." Biochemistry (Moscow) (2002), vol. 67 (1), pages 99-108	
/CMK./		COLLEN D.C. et al., "Thrombolytic agents." Thromb Haemost (2005), vol. 93, pages 627-30.	

Examiner Signature	/Chih Min Kam/	Date Considered	08/13/2010
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.